WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) Friday announced the start of the phase 2 trial for COVID-19 influenza combination and stand-alone influenza vaccine candidates.
The dose-confirming trial will be done in adults of 50 to 80 years to evaluate safety and effectiveness. The initial trial is scheduled for mid-year 2023.
The company said the Phase 2 dose-confirmation trial to be done in two parts will enroll approximately 2,300 participants across multiple sites in Australia and New Zealand.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News